AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 41 min read$CRL

Charles River Laboratories beats top-line and bottom-line estimates; updates FY26 outlook

Charles River Laboratories reported Q3 Non-GAAP EPS of $3.09, beating estimates by $0.12. Revenue was $982.7M, down 1.7% year-over-year but exceeding expectations by $22.34M. Organic revenue grew 4.7%. The company raised its 2026 guidance for revenue and non-GAAP EPS.

Original reporting
seekingalpha.com
Published Nov 4, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CRL
Bullish
high confidence
Mentioned
$CRL
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CRLBullishHigh
01

Why it matters

Earnings beat and guidance raise suggest near‑term upside for the stock.

02

Market read

The earnings surprise and guidance lift are material for traders with exposure to the CRO sector.

03

What to watch

Potential headwinds from client budget constraints or regulatory changes not reflected in the release.

Relevance 8/10Novelty 8/10Timing: immediate post‑release

Background

Charles River Laboratories reported Q3 results, beating estimates and raising FY26 outlook.

Company-level read

Ticker impact

$CRLBullishHigh confidence
Context

Q3 non‑GAAP EPS of $3.09 beats estimates and FY26 guidance is raised, providing fresh earnings and outlook data.

Expected impact

upward pressure as investors price in the earnings beat and higher guidance

Evidence & confidence

Both EPS and revenue beat expectations; guidance lift signals stronger future performance.

Market effects

Sector

May boost sentiment for the broader contract research organization (CRO) sector.

Regional

Positive for U.S. biotech and pharma service providers.

Global

Limited to investors tracking CRO earnings; no broader macro effect.

Counterpoint

What could challenge this read

If guidance is overly optimistic, the stock could face a pull‑back on subsequent quarters.

Key entities

  • Company
    Charles River Laboratories International, Inc.

    Provider of research models and services to pharma and biotech.

Read at source← All news

StoryCharles River Laboratories reports Q3 2026 earnings beat and raises 2026 outlook

Also covered by

5 outlets

Related articles

NOV 4
$CRLMedAI 8/10

Charles River Q3 2026 slides: organic growth returns but stock falls

Charles River Laboratories (CRL) reported Q3 2026 results with 4.7% organic revenue growth and non-GAAP EPS of $3.09, beating estimates. Despite this, shares fell 5.88% due to concerns over margin sustainability and delayed pricing power recovery. Revenue was $982.7M, with non-GAAP operating margin expanding to 23.0%. The DSA segment saw 5.9% organic growth, while Manufacturing grew 7.4% organically. Management expects pricing benefits to materialize in late 2027.

investing.com6 min
NOV 4
$CRLMedAI 8/10

Charles River Laboratories 2026: Revenue $982.73M, EPS $6.86— 10-Q Summary

Charles River Laboratories reported Q3 2026 revenue of $982.73M, down 2.2% YoY, while net income rose to $333.07M and EPS increased to $6.86. Management cited improving demand in Discovery and Safety Assessment, portfolio changes, and cost savings. Nine-month revenue declined 1.3%, with growth in microbial testing and China model sales. The company completed divestitures and acquisitions, targeting $300M in annual savings by 2026.

tradingview.com1 min
NOV 4
$CRLMed

Charles River Laboratories Lifts Annual Outlook- Update

Charles River Laboratories (CRL) raised its 2026 outlook, expecting revenue to decline 1.5%-2.0% (previously 2.5%-3.5%) and organic revenue to grow at least 1.5% (previously 0%-1%). EPS estimates increased to $8.15-$8.35 from $3.05-$3.35, with non-GAAP EPS at $11.35-$11.55. Q3 profit rose to $333.07M ($6.86/share) due to a $245.6M tax benefit, while revenue fell 2.1% to $982.732M. Shares dropped nearly 4% in pre-market trading.

rttnews.com2 min
NOV 4
$CRLHighAI 8/10

Charles River: Q3 Earnings Snapshot

Charles River Laboratories (CRL) reported Q3 net income of $333.1M, or $6.86 per share. Adjusted earnings were $3.09 per share, exceeding analyst estimates of $2.98 per share. Revenue was $982.7M, surpassing expectations of $956.8M. The company expects full-year earnings between $11.35 and $11.55 per share.

finance.yahoo.com2 min